Nano-TAB v0.5 Specification Development Effort Weekly Meeting June 8, 2010.

Slides:



Advertisements
Similar presentations
Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.
Advertisements

IWGT Group 4 Improving in vivo genotoxicity testing- the link to standard toxicity testing Summary of discussion items, conclusions and recommendations.
FCMAT Response & Preparation: Process Outline October 25, 2006.
Preclinical Drug Development Miss Sirikan Nawapan.
Workshop Highlights Relevant to Nano WG High Quality Data Sets - There is a critical need for high quality data sets as input to predictive models. This.
Evaluation of a potential mutagenic MOA based on analysis of the weight of evidence and using the modified Hill criteria Martha M. Moore, Ph.D. Director,
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
Informatics and standards for nanomedicine technology Dennis G. Thomas, Pacific Northwest National Lab Alan Chappell, Pacific Northwest National Lab Elaine.
1 Nano WG Activities for Current Period – NPO Related Establish formal processes incorporating JIRA tracker for Nanoparticle Ontology (NPO) governance.
APA Writing Style American Psychological Association. (2001). Publication manual of the American Psychological Association (5 th ed.). Washington, DC:
Geant4 Documentation and User Support Geant4 Users Workshop February 2002 Dennis Wright (SLAC)
Overview Nano WG The National Cancer Institute (NCI) caBIG® Nanotechnology Working Group (Nano WG) Jessica M. Adamick 1, Nathan A. Baker 2, Alan R. Chappell.
Guidance for Industry M4S: The CTD-Safety
ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.
Application of Toxicology Databases in Drug Development (Estimating potential toxicity) Joseph F. Contrera, Ph.D. Director, Regulatory Research and Analysis.
Writing the First Draft ENGL 3100 Dr. Shelley Thomas Based on Dr. Brenda Orbell’s original presentation.
Assays from the EU's Science Committee on Consumer Safety guidance document and from the EPA's conditional approval for HEIQ AG 20S Fred Klaessig, September.
CaNanoLab Data Curation Overview NCI Nano WG June 6, 2013.
Nanomaterial Registry: Minimal Information Standards for Well-Characterized Nanomaterials in Environmental and Biological Studies Michele L. Ostraat April.
1 st (RSBI) ISA-Tab Workshop – Scope and Outcome  Tackle today's need for exchange of multi-omics experiments Evaluate the ISA-TAB straw-man (incomplete)
Copyright OpenHelix. No use or reproduction without express written consent1.
Water Quality Planning Division Monitoring & Assessment Section Surface Water Quality Monitoring Program (SWQM)
The NCIP Nanotechnology Working Group Nano WG Fall 2013 Kick-Off.
UE Approach towards AUBI Design Patterns Adesh Singh 28 May 2008.
Your project title here Your name Construction Management University of Houston PROGRESS REPORT Reporting Period: From date – To date.
Cancer Nanotechnology Knowledgebase for Nanoparticle Analysis and Design caOBR-caB2B integration Nathan Baker, David Paik, and Persistent Systems.
Exploratory IND Studies
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
ISA-TAB-Nano A specification to facilitate data exchange among nanotechnology researchers and resources ISA-TAB-Nano
1 Nanomedicine informatics DENNIS G. THOMAS, PACIFIC NORTHWEST NATIONAL LAB ALAN CHAPPELL, PACIFIC NORTHWEST NATIONAL LAB ELAINE FREUND, 3 RD MILLENNIUM.
From Mice to Men, Cancers Are Not Certain At Old Age Francesco Pompei, Ph.D. and Richard Wilson, D.Phil. Harvard University Presented at the Belle Non-Linear.
DCIPS Implementation Project Plan Update Army G2 Intelligence Personnel Management Office (IPMO) April 6, 2009.
NCI Nano WG & ISA-TAB-Nano Overview March What is the caBIG ® Nanotechnology Working Group? NCI: National Cancer Institute –caBIG ® : Cancer Biomedical.
CaNanoLab Users Group February 2012 Use of Informatics to Expedite and Validate the Application of Nanotechnology in Biomedicine.
CA-1 Preclinical Studies Philip Bentley, PhD Vice President Toxicology/Pathology Novartis Pharmaceuticals Corporation Philip Bentley, PhD Vice President.
1 Nanotechnology Working Group Nathan Baker Report to Integrative Cancer Research Workspace January 11, 2012.
CaNanoLab Users Group Use of Informatics to Expedite and Validate the Application of Nanotechnology in Biomedicine August 2, 2012.
ISA-TAB-Nano Weekly Meeting May 1, 2012 Use of Informatics to Expedite and Validate the Application of Nanotechnology in Biomedicine.
Introduction Topic: The Effects of Bisphenol A on Animals During Prenatal Exposure Topic: The Effects of Bisphenol A on Animals During Prenatal Exposure.
Copyright OpenHelix. No use or reproduction without express written consent1.
Kamala Pant, M.S. BioReliance Study Director/Principal Scientist
July 06, 2006 – TAC Meeting 1 TPTF Update Trip Doggett.
Copyright © 2009 Intel Corporation. All rights reserved. Intel, the Intel logo, Intel Education Initiative, and the Intel Teach Program are trademarks.
Insert Nonprofit Logo Project Name Mid-Development Presentation.
A Literature Review to Investigate if Blood Compatibility Tests are a Necessary Procedure in the Pharmaceutical Industry to Predict Adverse Toxicology.
The Value of Digital Photography By Louise Rutherford and Dean Hatt.
Furan-Induced Cytotoxicity, Cell Proliferation, and Tumorgenicity in Mouse Liver Dr. Glenda Moser.
Pediatric Subcommittee of the AIDAC October 29-30, Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology October 30, 2003 Barbara.
Longitudinal Coordination of Care LCP SWG Thursday, May 23, 2013.
Data types Microarray, etc. –Exchange format well established –MIAME convention, et al. Clinical chemistry, hematology, measurements –Generally a spreadsheet.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
CaNanoLab Data Curation Overview NCI Nano WG June 6, 2013.
1 LS DAM Overview August 7, 2012 Current Core Team: Ian Fore, D.Phil., NCI CBIIT, Robert Freimuth, Ph.D., Mayo Clinic, Mervi Heiskanen, NCI-CBIIT, Joyce.
James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.
Ongoing studies Full scale study for assessing bioavailability, uptake, biodistribution and maternal transfer of nano (7nm) vs bulk sized Ag MNMs. Full.
CaNanoLab Users Group  Building a collaborative environment enabling data sharing in the biomedical nanotechnology research community Oct. 17, 2008.
CaNanoLab Users Group April 2012 Use of Informatics to Expedite and Validate the Application of Nanotechnology in Biomedicine.
Knowledgebase of Nanomaterial-Biological Interactions and nano-TAB caBIG ICR F2F Stacey Harper, PhD Oregon State Sharon Gaheen, SAIC May 6, 2010.
Annual Ramazzini Days Carpi, October 28th , 2016
Drug Candidate-Induced Changes in the Thyroid Gland: Contrasting Case Studies Joan Lane, Katie Zokowski, Jeffrey Horrigan, Daniel Aleksandrowicz, Doriana.
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Pre-Investigational New Drug (pre-IND) Meeting with FDA
EVALUATION OF THE POTENTIAL IN VIVO GENOTOXICITY OF QUERCETIN
Introduction to Environmental Engineering and Science (3rd ed.)
First insight into the effect of single oral dose therapy with artemisinin –naphthoquine phosphate combination in a mouse model of Schistosoma mansoni.
Body weight at harvest (g) Left kidney:body weight ratio (g/kg)
MGED Ontology Working Group Report
University Template Sample Slides June 2017.
Rational for the 5R Philosophy
NRRA Pavement Workshop 2019
Presentation transcript:

nano-TAB v0.5 Specification Development Effort Weekly Meeting June 8, 2010

Agenda Review NTP Study and Example Files Follow-up on Actions Review Project Status and Discuss Next Steps

NTP Fullerene-C60 Study

Toxicology/Carcinogenicity Studies

13-Week Toxicity Study Protocol

DRAFT Investigation and Studies (1 of 2) INVESTIGATION TITLE: 90 Day Toxicity Study for Nanoscale material (Fullerene-C60) DESCRIPTION: Obtain toxicological data and determine the treatments for each strain and species to be used in the 2-year toxicology/carcinogenesis study STUDY #1: TITLE: Standard Toxicology and Carcinogenesis Studies DESCRIPTION: Analysis of rats and mice of both sexes exposed to concentrations of fullerene-C60 for a period of 13 weeks. DESIGN: exposure; time course; compound based treatment FACTORS: duration of exposure; dose; compound; strain; sex ASSAYS: ASSAY MEASUREMENTS: body weight ASSAY TECHNOLOGY TYPE: PROTOCOLS: PROTOCOL NAME: 13-Week Toxicity Study PROTOCOL PARAMETERS: duration of exposure; compound; dose; route of exposure; strain; sex; diet; cage group; sacrifice method

DRAFT Investigation and Studies (2 of 2) STUDY #2: TITLE: Genetic Toxicology Study DESCRIPTION: Analysis of the frequency of micronucleated erythrocytes in rats and mice of both sexes exposed to concentrations of fullerene-C60 for a period of 13 week as an in vivo measure of genotoxic potential DESIGN: exposure; time course; compound based treatment FACTORS: duration of exposure; dose; compound; strain; sex ASSAYS: ASSAY MEASUREMENTS: total MN cells, percent PCD, MC cells per 1000 ASSAY TECHNOLOGY TYPE: PROTOCOLS: PROTOCOL NAME: 13-Week Toxicity Study PROTOCOL PARAMETERS: duration of exposure; compound; dose; route of exposure; strain; sex; diet; cage group; sacrifice method

DRAFT NTP Investigation File (1 of 3)

DRAFT NTP Investigation File (2 of 3)

DRAFT NTP Investigation File (3 of 3)

Study Samples Nanomaterial SOURCE: SAMPLE NAME: MATERIAL TYPE: fullerene CHARACTERISTICS: description: fullerene C-60 number of carbons: 60 Diameter (?): 1 micron; 50 nanometers Biological Material SOURCE: B6C ; Wistar ; (Animal ID ) SAMPLE NAME: B6C ; Wistar ; (Animal ID ) MATERIAL TYPE: whole organism CHARACTERISTICS organism: mice; rats strain: B6C3F1; Wistar Han sex: male; female PROTOCOL REF PARAMETER VALUE compound: duration of exposure: 90 days FACTOR VALUE dose: vehicle control; 0.5; 2.0 unit: mg/m3

Study-Sample Files - Material

Study-Sample Files - Animals (1 of 2)

Study-Sample Files- Animals (2 of 2)

Standard Toxicology & Carcinogenesis Studies

Study Search Criteria

Body Weight Results

Body Weight Assay File (1 of 2)

Body Weight Assay File (2 of 2)

Micronucleus Study

Micronucleus Study Search

Summary Results

Detailed Results

Individual Animal Data

Micronucleus Assay File TBD

Agenda Review NTP Study and Example Files Follow-up on Actions Review Project Status and Discuss Next Steps

Follow-up on Actions ActionAssigned To Draft example files for the NTP dataSharon Gaheen Identify top ten (10) nanotechnology assays leveraging ASTM protocolsStacey Harper Marty Fritts Continue to update nano-TAB filesSharon Gaheen Stacey Harper Continue to update the NPO in support of nano-TAB termsDennis Thomas

Agenda Review NTP Study and Example Files Follow-up on Actions Review Project Status and Discuss Next Steps

Project Status

Next Steps Continue review/update of nano-TAB files Update files based on feedback from the 6/11 ISA-TAB discussion Create assay files for prioritized ASTM assays Continue drafting assays files for NTP nanomaterial studies and review with the NTP Continue collaborations with the ISA-TAB organization Schedule next meeting for early June (est. June 11) Obtain overview of ISA-TAB tools Continue updating NPO in support of nano-TAB ontology needs Begin drafting nano-TAB specification ( Specification Summary – Sharon Gaheen Section 1: Introduction – Stacey Harper Section 2: nano-TAB Structure – Sharon Gaheen, Stacey Harper, and Raul Cachua (Structures) Section 3: Relationships to Standards – Dennis Thomas, Nathan Baker (ASTM) Section 4: nano-TAB Details - Sharon Gaheen, Stacey Harper, Dennis Thomas, and Raul Cachua (Structures) Section 5: References – TBD Document Review – All Team Members Review/update nano-TAB timeline Next meeting: Tuesday, June 15, 11:00-12:00

References Nano-TAB &language_id=1http://gforge.nci.nih.gov/docman/index.php?group_id=69&selected_doc_group_id= 5653&language_id=1 LS DAM Nano Subdomain DAM%20R1_2.EAP?root=lsdamhttps://gforge.nci.nih.gov/plugins/scmsvn/viewcvs.php/*checkout*/requirements/LS DAM%20R1_2.EAP?root=lsdam caBIG ICR Nano Data Standards Document standards/data-sharing-standardshttp://sites.google.com/site/cabignanowg/data-sharing-and-nanotechnology- standards/data-sharing-standards MAGE-TAB ISA-TAB